Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A419Q2 | ISIN: US71902K4022 | Ticker-Symbol:
NASDAQ
23.10.25 | 22:00
2,000 US-Dollar
-0,50 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERO THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CERO THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur CERO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML128Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings...
► Artikel lesen
16.10.Cero Therapeutics passt Kaufvertrag an und sichert sich 2,25 Mio. US-Dollar im ersten Closing3
15.10.CERo Therapeutics Holdings, Inc.: CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 20252
14.10.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report4
13.10.CERo Therapeutics completes first cohort in AML clinical trial2
13.10.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML113Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published...
► Artikel lesen
10.10.CERo Therapeutics open to takeover offers as it awaits key data - Axios9
10.10.CERo Therapeutics signalisiert vor wichtigen Studiendaten Verkaufsbereitschaft2
CERO THERAPEUTICS Aktie jetzt für 0€ handeln
22.09.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report1
22.09.CERo Therapeutics doses third patient in AML clinical trial1
22.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort189Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO...
► Artikel lesen
09.09.CERo Therapeutics secures key patent protection for cancer therapy1
09.09.CERo Therapeutics sichert wichtigen US-Patentschutz für Krebstherapie3
09.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 20411
08.09.CERo Therapeutics administers second dose in AML clinical trial1
08.09.CERo Therapeutics verabreicht zweite Dosis in klinischer AML-Studie2
08.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia84Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE...
► Artikel lesen
05.09.CERo Therapeutics Stock Drops 13% Despite FDA Fast Track For Lead AML Therapy1
05.09.CERo Therapeutics Holdings, Inc.: CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)185Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program SOUTH SAN FRANSCISCO...
► Artikel lesen
04.09.CERO THERAPEUTICS HOLDINGS, INC. - 8-K, Current Report1
Weiter >>
70 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1